Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Major Depressive Disorder
NCT01179516Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Takeda. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Started Aug 2010; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01179516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01179516.